drug
apremilast ER
Marketedupdated 6mo agoby $AMGN AMGEN INC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugOTEZLA31 co-mentions · 17 sources
- tagApproval28 co-mentions · 14 sources
- drugapremilast17 co-mentions · 17 sources
- company$AMGNAMGEN INC14 co-mentions · 14 sources
- tagSmall Molecule14 co-mentions · 14 sources
- companyUniversity of Colorado Denver1 co-mentions · 1 sources
- companyUniversity of California Los Angeles1 co-mentions · 1 sources
- companyUniversity of Virginia1 co-mentions · 1 sources
all catalysts(0)
nothing on the calendar yet
Trials studying apremilast ER
- phase3A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
- phase3Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
- phase4Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.
- phase3A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
- phase3A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
- phase3A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
- phase3A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
- phase3HPP737 in Adult Patients With Plaque Psoriasis
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that